Advancing LNP characterization for drug delivery: NeoVac

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Advancing LNP characterization for drug delivery: NeoVac

Lipid nanoparticles (LNPs) are cell-specific delivery systems capable of encapsulating various payloads, including different nucleic acids. Their characterization proves to be a significant challenge due to their complex composition and structure.

Customer experience highlight:

Dan Peer from Tel Aviv University/NeoVac Ltd. and Tristan Kovacic from Sartorius BIA Separations share challenges and achievements in developing LNP formulations. NeoVac leveraged the PATfix LNP Switcher to enhance the safety and reliability of their LNP-based therapeutics. The system has become an invaluable tool in their process development and optimization efforts, providing quick and comprehensive insights into every step of their LNP formulation process.

Feature demonstration:

The PATfix LNP Switcher offers a unique characterization approach to LNP formulations, addressing the limitations of traditional assays that often require multiple time-consuming steps. Utilizing an innovative 2D chromatographic method with two different separation stages, the PATfix Switcher determines crucial LNP quality attributes in a single run without any sample preparation. Unlike other assays, it allows for simultaneous quantification of both encapsulated and naked nucleic acid cargo, including co-encapsulated species, and provides estimates of mRNA fragmentation and LNP size.

Understand the key parameters for characterizing LNPs
Discover liquid chromatography methods for encapsulation efficiency, lipid composition, load integrity, and size analysis
Hear from NeoVac how the PATfix LNP Switcher system has become crucial in enhancing the safety and reliability of LNP formulations by providing comprehensive insights into their development and optimization
Participate in an interactive Q&A session to enhance your LNP characterization processes

This webinar is part of the “Biopharmaceutical analytics unveiled: expert insights and customer success stories” virtual event. To view the other sessions, click on the links below:

Session 1- Enhancing pDNA Production for Gene Therapy: BioNTech

Session 2 - Enhancing mRNA production with advanced analytics: WACKER Biotech

Session 4 - Accelerating AAV process development: NCSU BTEC

Tristan Kovačič

Scientist, Process Analytics Development Department at Sartorius BIA Separations

Tristan is a Scientist in the Process Analytics Development Department at Sartorius BIA Separations and a PhD student in Computational Chemistry at the University of Maribor. He holds an MSci degree in Chemistry from Imperial College London. He has experience in the pharmaceutical and biotech industries, focusing on process development and analytics for non-viral drug delivery systems and active pharmaceutical ingredients.

Blaz Bakalar

Product Manager, PATfix® Platform at Sartorius BIA Separations

Blaz completed his BSc in Biochemistry at the University of Ljubljana, Slovenia, with the program having a heavy focus on laboratory methods widely used in the pharmaceutical industry. He obtained his PhD at NTU Singapore, with a focus on nucleic acid biophysics. In 2020 he joined Sartorius BIA Separations as the PATfix product manager. The PATfix analytical platform combines hardware, software and BIA analytical know-how into a single platform package, making his previous experience a valuable contributor in steering the product towards success.

Dan Peer

Chairman at NeoVac

Dan Peer is the chairman of NeoVac as well as a professor and the director of the Laboratory of precision NanoMedicine at Tel Aviv University. His lab was the first to show systemic, high efficiency, cell specific, therapeutic genome editing in cancer.